1 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
| 1 | 35377866 | A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. | 2022 Jun 1 | 1 |